nodes	percent_of_prediction	percent_of_DWPC	metapath
Nateglinide—PPARG—urinary bladder cancer	0.455	1	CbGaD
Nateglinide—SLC16A1—Methotrexate—urinary bladder cancer	0.0745	0.222	CbGbCtD
Nateglinide—ABCC4—Fluorouracil—urinary bladder cancer	0.0649	0.193	CbGbCtD
Nateglinide—ABCC4—Methotrexate—urinary bladder cancer	0.0358	0.107	CbGbCtD
Nateglinide—PTGS1—Etoposide—urinary bladder cancer	0.0269	0.0801	CbGbCtD
Nateglinide—ALB—Fluorouracil—urinary bladder cancer	0.0241	0.0717	CbGbCtD
Nateglinide—CYP3A4—Thiotepa—urinary bladder cancer	0.0232	0.0691	CbGbCtD
Nateglinide—CYP3A5—Etoposide—urinary bladder cancer	0.0161	0.0481	CbGbCtD
Nateglinide—SLC22A6—Methotrexate—urinary bladder cancer	0.0156	0.0464	CbGbCtD
Nateglinide—ALB—Methotrexate—urinary bladder cancer	0.0133	0.0395	CbGbCtD
Nateglinide—CYP2C9—Fluorouracil—urinary bladder cancer	0.013	0.0386	CbGbCtD
Nateglinide—CYP2C9—Cisplatin—urinary bladder cancer	0.011	0.0328	CbGbCtD
Nateglinide—ABCC8—penis—urinary bladder cancer	0.00774	0.132	CbGeAlD
Nateglinide—CYP2D6—Doxorubicin—urinary bladder cancer	0.00675	0.0201	CbGbCtD
Nateglinide—CYP3A4—Etoposide—urinary bladder cancer	0.00629	0.0187	CbGbCtD
Nateglinide—Flu symptoms—Gemcitabine—urinary bladder cancer	0.00451	0.0749	CcSEcCtD
Nateglinide—CYP3A4—Doxorubicin—urinary bladder cancer	0.00429	0.0128	CbGbCtD
Nateglinide—CYP2C9—urine—urinary bladder cancer	0.0023	0.0392	CbGeAlD
Nateglinide—PPARG—Teniposide—Etoposide—urinary bladder cancer	0.0021	1	CbGdCrCtD
Nateglinide—Mitiglinide—UGT2B7—urinary bladder cancer	0.00198	0.423	CrCbGaD
Nateglinide—UGT1A9—renal system—urinary bladder cancer	0.00196	0.0333	CbGeAlD
Nateglinide—Aspartame—TRPV1—urinary bladder cancer	0.00193	0.412	CrCbGaD
Nateglinide—ABCC8—prostate gland—urinary bladder cancer	0.00185	0.0315	CbGeAlD
Nateglinide—CYP3A4—urine—urinary bladder cancer	0.00176	0.0299	CbGeAlD
Nateglinide—CYP2D6—urine—urinary bladder cancer	0.00173	0.0294	CbGeAlD
Nateglinide—SLC16A1—prostate gland—urinary bladder cancer	0.00168	0.0286	CbGeAlD
Nateglinide—ABCC8—seminal vesicle—urinary bladder cancer	0.00156	0.0266	CbGeAlD
Nateglinide—ORM1—prostate gland—urinary bladder cancer	0.00151	0.0257	CbGeAlD
Nateglinide—PPARG—prostate gland—urinary bladder cancer	0.00141	0.024	CbGeAlD
Nateglinide—Oedema peripheral—Valrubicin—urinary bladder cancer	0.00133	0.022	CcSEcCtD
Nateglinide—Gastrointestinal symptom NOS—Fluorouracil—urinary bladder cancer	0.00131	0.0217	CcSEcCtD
Nateglinide—ABCC8—smooth muscle tissue—urinary bladder cancer	0.00131	0.0223	CbGeAlD
Nateglinide—SLC15A1—epithelium—urinary bladder cancer	0.0013	0.0221	CbGeAlD
Nateglinide—ABCC4—prostate gland—urinary bladder cancer	0.00128	0.0218	CbGeAlD
Nateglinide—ABCC8—renal system—urinary bladder cancer	0.00126	0.0215	CbGeAlD
Nateglinide—SLC16A1—epithelium—urinary bladder cancer	0.00124	0.021	CbGeAlD
Nateglinide—SLC15A1—renal system—urinary bladder cancer	0.0012	0.0205	CbGeAlD
Nateglinide—SLC16A1—renal system—urinary bladder cancer	0.00115	0.0195	CbGeAlD
Nateglinide—Back pain—Valrubicin—urinary bladder cancer	0.00114	0.0188	CcSEcCtD
Nateglinide—SLC15A2—prostate gland—urinary bladder cancer	0.0011	0.0188	CbGeAlD
Nateglinide—KCNJ11—female reproductive system—urinary bladder cancer	0.0011	0.0187	CbGeAlD
Nateglinide—PPARG—epithelium—urinary bladder cancer	0.00104	0.0177	CbGeAlD
Nateglinide—PPARG—smooth muscle tissue—urinary bladder cancer	0.000999	0.017	CbGeAlD
Nateglinide—PPARG—renal system—urinary bladder cancer	0.000962	0.0164	CbGeAlD
Nateglinide—PPARG—urethra—urinary bladder cancer	0.000945	0.0161	CbGeAlD
Nateglinide—SLC15A2—seminal vesicle—urinary bladder cancer	0.000934	0.0159	CbGeAlD
Nateglinide—SLC16A1—female reproductive system—urinary bladder cancer	0.000918	0.0156	CbGeAlD
Nateglinide—ABCC4—renal system—urinary bladder cancer	0.000873	0.0149	CbGeAlD
Nateglinide—SLC15A1—vagina—urinary bladder cancer	0.000872	0.0149	CbGeAlD
Nateglinide—CYP3A5—prostate gland—urinary bladder cancer	0.00084	0.0143	CbGeAlD
Nateglinide—Hepatic enzyme increased—Gemcitabine—urinary bladder cancer	0.000828	0.0137	CcSEcCtD
Nateglinide—ORM1—female reproductive system—urinary bladder cancer	0.000824	0.014	CbGeAlD
Nateglinide—Gastrointestinal pain—Valrubicin—urinary bladder cancer	0.000784	0.013	CcSEcCtD
Nateglinide—Mitiglinide—PPARG—urinary bladder cancer	0.000773	0.165	CrCbGaD
Nateglinide—PPARG—female reproductive system—urinary bladder cancer	0.00077	0.0131	CbGeAlD
Nateglinide—Abdominal pain—Valrubicin—urinary bladder cancer	0.000758	0.0126	CcSEcCtD
Nateglinide—PTGS1—prostate gland—urinary bladder cancer	0.000754	0.0128	CbGeAlD
Nateglinide—SLC15A2—renal system—urinary bladder cancer	0.000753	0.0128	CbGeAlD
Nateglinide—SLC15A2—urethra—urinary bladder cancer	0.00074	0.0126	CbGeAlD
Nateglinide—Cough—Mitomycin—urinary bladder cancer	0.000706	0.0117	CcSEcCtD
Nateglinide—ABCC4—female reproductive system—urinary bladder cancer	0.000699	0.0119	CbGeAlD
Nateglinide—PPARG—vagina—urinary bladder cancer	0.000697	0.0119	CbGeAlD
Nateglinide—Asthenia—Valrubicin—urinary bladder cancer	0.000688	0.0114	CcSEcCtD
Nateglinide—Pruritus—Valrubicin—urinary bladder cancer	0.000678	0.0112	CcSEcCtD
Nateglinide—Diarrhoea—Valrubicin—urinary bladder cancer	0.000656	0.0109	CcSEcCtD
Nateglinide—KCNJ11—lymph node—urinary bladder cancer	0.000641	0.0109	CbGeAlD
Nateglinide—PTGS1—seminal vesicle—urinary bladder cancer	0.000638	0.0109	CbGeAlD
Nateglinide—Dizziness—Valrubicin—urinary bladder cancer	0.000634	0.0105	CcSEcCtD
Nateglinide—Vomiting—Valrubicin—urinary bladder cancer	0.000609	0.0101	CcSEcCtD
Nateglinide—Rash—Valrubicin—urinary bladder cancer	0.000604	0.01	CcSEcCtD
Nateglinide—Dermatitis—Valrubicin—urinary bladder cancer	0.000604	0.01	CcSEcCtD
Nateglinide—Polyuria—Cisplatin—urinary bladder cancer	0.000603	0.01	CcSEcCtD
Nateglinide—SLC15A2—female reproductive system—urinary bladder cancer	0.000603	0.0103	CbGeAlD
Nateglinide—CYP3A5—renal system—urinary bladder cancer	0.000572	0.00974	CbGeAlD
Nateglinide—Nausea—Valrubicin—urinary bladder cancer	0.000569	0.00944	CcSEcCtD
Nateglinide—Fatigue—Mitomycin—urinary bladder cancer	0.000569	0.00944	CcSEcCtD
Nateglinide—Osteoarthritis—Fluorouracil—urinary bladder cancer	0.000559	0.00927	CcSEcCtD
Nateglinide—PTGS1—epithelium—urinary bladder cancer	0.000554	0.00944	CbGeAlD
Nateglinide—SLC15A2—vagina—urinary bladder cancer	0.000545	0.00929	CbGeAlD
Nateglinide—SLC16A1—lymph node—urinary bladder cancer	0.000537	0.00914	CbGeAlD
Nateglinide—PTGS1—smooth muscle tissue—urinary bladder cancer	0.000534	0.00909	CbGeAlD
Nateglinide—PTGS1—renal system—urinary bladder cancer	0.000514	0.00875	CbGeAlD
Nateglinide—Jaundice—Thiotepa—urinary bladder cancer	0.000508	0.00842	CcSEcCtD
Nateglinide—Hepatobiliary disease—Thiotepa—urinary bladder cancer	0.000492	0.00817	CcSEcCtD
Nateglinide—Influenza—Gemcitabine—urinary bladder cancer	0.000491	0.00815	CcSEcCtD
Nateglinide—ORM1—lymph node—urinary bladder cancer	0.000482	0.00821	CbGeAlD
Nateglinide—Asthenia—Mitomycin—urinary bladder cancer	0.000474	0.00786	CcSEcCtD
Nateglinide—Diarrhoea—Mitomycin—urinary bladder cancer	0.000452	0.00749	CcSEcCtD
Nateglinide—CYP2C9—female reproductive system—urinary bladder cancer	0.000451	0.00768	CbGeAlD
Nateglinide—PPARG—lymph node—urinary bladder cancer	0.000451	0.00767	CbGeAlD
Nateglinide—Upper respiratory tract infection—Fluorouracil—urinary bladder cancer	0.000449	0.00744	CcSEcCtD
Nateglinide—Sweating increased—Cisplatin—urinary bladder cancer	0.000446	0.0074	CcSEcCtD
Nateglinide—Dizziness—Mitomycin—urinary bladder cancer	0.000437	0.00724	CcSEcCtD
Nateglinide—CYP3A4—renal system—urinary bladder cancer	0.000429	0.00731	CbGeAlD
Nateglinide—Neuropathy peripheral—Gemcitabine—urinary bladder cancer	0.000429	0.00712	CcSEcCtD
Nateglinide—Hepatic enzyme increased—Methotrexate—urinary bladder cancer	0.000423	0.00702	CcSEcCtD
Nateglinide—ALB—lymph node—urinary bladder cancer	0.000423	0.0072	CbGeAlD
Nateglinide—CYP2D6—renal system—urinary bladder cancer	0.000423	0.0072	CbGeAlD
Nateglinide—Immune system disorder—Thiotepa—urinary bladder cancer	0.000422	0.007	CcSEcCtD
Nateglinide—Neuropathy peripheral—Fluorouracil—urinary bladder cancer	0.000422	0.007	CcSEcCtD
Nateglinide—Sweating—Gemcitabine—urinary bladder cancer	0.00042	0.00696	CcSEcCtD
Nateglinide—Vomiting—Mitomycin—urinary bladder cancer	0.00042	0.00696	CcSEcCtD
Nateglinide—Rash—Mitomycin—urinary bladder cancer	0.000416	0.0069	CcSEcCtD
Nateglinide—Dermatitis—Mitomycin—urinary bladder cancer	0.000416	0.0069	CcSEcCtD
Nateglinide—CYP3A5—vagina—urinary bladder cancer	0.000414	0.00706	CbGeAlD
Nateglinide—Hepatobiliary disease—Gemcitabine—urinary bladder cancer	0.000414	0.00687	CcSEcCtD
Nateglinide—Arthropathy—Epirubicin—urinary bladder cancer	0.000412	0.00683	CcSEcCtD
Nateglinide—PTGS1—female reproductive system—urinary bladder cancer	0.000412	0.00701	CbGeAlD
Nateglinide—ABCC4—lymph node—urinary bladder cancer	0.000409	0.00697	CbGeAlD
Nateglinide—Sweating increased—Etoposide—urinary bladder cancer	0.000409	0.00678	CcSEcCtD
Nateglinide—Malnutrition—Thiotepa—urinary bladder cancer	0.000407	0.00675	CcSEcCtD
Nateglinide—Neuropathy peripheral—Cisplatin—urinary bladder cancer	0.0004	0.00664	CcSEcCtD
Nateglinide—Back pain—Thiotepa—urinary bladder cancer	0.000394	0.00653	CcSEcCtD
Nateglinide—Nausea—Mitomycin—urinary bladder cancer	0.000392	0.0065	CcSEcCtD
Nateglinide—Oedema peripheral—Gemcitabine—urinary bladder cancer	0.000387	0.00642	CcSEcCtD
Nateglinide—Hepatobiliary disease—Cisplatin—urinary bladder cancer	0.000386	0.0064	CcSEcCtD
Nateglinide—Arthropathy—Doxorubicin—urinary bladder cancer	0.000381	0.00632	CcSEcCtD
Nateglinide—PTGS1—vagina—urinary bladder cancer	0.000372	0.00634	CbGeAlD
Nateglinide—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.000372	0.00616	CcSEcCtD
Nateglinide—Neuropathy peripheral—Etoposide—urinary bladder cancer	0.000367	0.00608	CcSEcCtD
Nateglinide—Jaundice—Etoposide—urinary bladder cancer	0.000365	0.00605	CcSEcCtD
Nateglinide—Urine output increased—Methotrexate—urinary bladder cancer	0.000362	0.006	CcSEcCtD
Nateglinide—Immune system disorder—Gemcitabine—urinary bladder cancer	0.000355	0.00589	CcSEcCtD
Nateglinide—Cough—Thiotepa—urinary bladder cancer	0.000355	0.00589	CcSEcCtD
Nateglinide—Hepatobiliary disease—Etoposide—urinary bladder cancer	0.000354	0.00587	CcSEcCtD
Nateglinide—SLC15A2—lymph node—urinary bladder cancer	0.000353	0.00601	CbGeAlD
Nateglinide—CYP3A4—female reproductive system—urinary bladder cancer	0.000344	0.00586	CbGeAlD
Nateglinide—CYP2D6—female reproductive system—urinary bladder cancer	0.000338	0.00576	CbGeAlD
Nateglinide—Back pain—Gemcitabine—urinary bladder cancer	0.000331	0.00549	CcSEcCtD
Nateglinide—Polyuria—Methotrexate—urinary bladder cancer	0.000331	0.00549	CcSEcCtD
Nateglinide—Immune system disorder—Cisplatin—urinary bladder cancer	0.000331	0.00549	CcSEcCtD
Nateglinide—Malnutrition—Cisplatin—urinary bladder cancer	0.000319	0.00529	CcSEcCtD
Nateglinide—Erythema multiforme—Etoposide—urinary bladder cancer	0.000317	0.00526	CcSEcCtD
Nateglinide—Immune system disorder—Etoposide—urinary bladder cancer	0.000303	0.00503	CcSEcCtD
Nateglinide—Tremor—Cisplatin—urinary bladder cancer	0.000299	0.00496	CcSEcCtD
Nateglinide—Cough—Gemcitabine—urinary bladder cancer	0.000299	0.00495	CcSEcCtD
Nateglinide—Dyspepsia—Thiotepa—urinary bladder cancer	0.000292	0.00485	CcSEcCtD
Nateglinide—Osteoarthritis—Methotrexate—urinary bladder cancer	0.000291	0.00482	CcSEcCtD
Nateglinide—Increased appetite—Epirubicin—urinary bladder cancer	0.00029	0.0048	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000287	0.00475	CcSEcCtD
Nateglinide—Fatigue—Thiotepa—urinary bladder cancer	0.000286	0.00475	CcSEcCtD
Nateglinide—Back pain—Etoposide—urinary bladder cancer	0.000283	0.00469	CcSEcCtD
Nateglinide—Hypoglycaemia—Epirubicin—urinary bladder cancer	0.000279	0.00462	CcSEcCtD
Nateglinide—Osteoarthritis—Epirubicin—urinary bladder cancer	0.000272	0.00451	CcSEcCtD
Nateglinide—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000272	0.0045	CcSEcCtD
Nateglinide—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.00027	0.00448	CcSEcCtD
Nateglinide—Increased appetite—Doxorubicin—urinary bladder cancer	0.000268	0.00444	CcSEcCtD
Nateglinide—Urticaria—Thiotepa—urinary bladder cancer	0.000264	0.00437	CcSEcCtD
Nateglinide—Abdominal pain—Thiotepa—urinary bladder cancer	0.000263	0.00435	CcSEcCtD
Nateglinide—Hypoglycaemia—Doxorubicin—urinary bladder cancer	0.000258	0.00428	CcSEcCtD
Nateglinide—Cough—Etoposide—urinary bladder cancer	0.000255	0.00423	CcSEcCtD
Nateglinide—Osteoarthritis—Doxorubicin—urinary bladder cancer	0.000252	0.00417	CcSEcCtD
Nateglinide—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000252	0.00417	CcSEcCtD
Nateglinide—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000245	0.00406	CcSEcCtD
Nateglinide—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000242	0.00401	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000241	0.004	CcSEcCtD
Nateglinide—PTGS1—lymph node—urinary bladder cancer	0.000241	0.0041	CbGeAlD
Nateglinide—Fatigue—Gemcitabine—urinary bladder cancer	0.000241	0.00399	CcSEcCtD
Nateglinide—Asthenia—Thiotepa—urinary bladder cancer	0.000238	0.00395	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000237	0.00393	CcSEcCtD
Nateglinide—Influenza—Epirubicin—urinary bladder cancer	0.000235	0.0039	CcSEcCtD
Nateglinide—Pruritus—Thiotepa—urinary bladder cancer	0.000235	0.0039	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000234	0.00387	CcSEcCtD
Nateglinide—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000231	0.00382	CcSEcCtD
Nateglinide—Diarrhoea—Thiotepa—urinary bladder cancer	0.000227	0.00377	CcSEcCtD
Nateglinide—Bronchitis—Epirubicin—urinary bladder cancer	0.000226	0.00375	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000225	0.00373	CcSEcCtD
Nateglinide—Dizziness—Thiotepa—urinary bladder cancer	0.00022	0.00364	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000219	0.00362	CcSEcCtD
Nateglinide—Urticaria—Fluorouracil—urinary bladder cancer	0.000218	0.00362	CcSEcCtD
Nateglinide—Influenza—Doxorubicin—urinary bladder cancer	0.000218	0.00361	CcSEcCtD
Nateglinide—Sweating—Methotrexate—urinary bladder cancer	0.000215	0.00356	CcSEcCtD
Nateglinide—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000212	0.00351	CcSEcCtD
Nateglinide—Vomiting—Thiotepa—urinary bladder cancer	0.000211	0.0035	CcSEcCtD
Nateglinide—Rash—Thiotepa—urinary bladder cancer	0.000209	0.00347	CcSEcCtD
Nateglinide—Bronchitis—Doxorubicin—urinary bladder cancer	0.000209	0.00347	CcSEcCtD
Nateglinide—Dermatitis—Thiotepa—urinary bladder cancer	0.000209	0.00347	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000206	0.00342	CcSEcCtD
Nateglinide—Fatigue—Etoposide—urinary bladder cancer	0.000206	0.00341	CcSEcCtD
Nateglinide—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000205	0.00341	CcSEcCtD
Nateglinide—Jaundice—Epirubicin—urinary bladder cancer	0.000204	0.00339	CcSEcCtD
Nateglinide—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000202	0.00336	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000202	0.00335	CcSEcCtD
Nateglinide—Sweating—Epirubicin—urinary bladder cancer	0.000201	0.00333	CcSEcCtD
Nateglinide—Asthenia—Gemcitabine—urinary bladder cancer	0.0002	0.00332	CcSEcCtD
Nateglinide—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000198	0.00329	CcSEcCtD
Nateglinide—Pruritus—Gemcitabine—urinary bladder cancer	0.000198	0.00328	CcSEcCtD
Nateglinide—Nausea—Thiotepa—urinary bladder cancer	0.000197	0.00327	CcSEcCtD
Nateglinide—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000195	0.00323	CcSEcCtD
Nateglinide—Pruritus—Fluorouracil—urinary bladder cancer	0.000194	0.00322	CcSEcCtD
Nateglinide—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000192	0.00318	CcSEcCtD
Nateglinide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000191	0.00317	CcSEcCtD
Nateglinide—Erythema multiforme—Methotrexate—urinary bladder cancer	0.00019	0.00315	CcSEcCtD
Nateglinide—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.00019	0.00315	CcSEcCtD
Nateglinide—Urticaria—Etoposide—urinary bladder cancer	0.000189	0.00314	CcSEcCtD
Nateglinide—Jaundice—Doxorubicin—urinary bladder cancer	0.000189	0.00314	CcSEcCtD
Nateglinide—Abdominal pain—Etoposide—urinary bladder cancer	0.000189	0.00313	CcSEcCtD
Nateglinide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000188	0.00312	CcSEcCtD
Nateglinide—Asthenia—Cisplatin—urinary bladder cancer	0.000187	0.0031	CcSEcCtD
Nateglinide—Sweating—Doxorubicin—urinary bladder cancer	0.000186	0.00308	CcSEcCtD
Nateglinide—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000185	0.00307	CcSEcCtD
Nateglinide—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000183	0.00304	CcSEcCtD
Nateglinide—Immune system disorder—Methotrexate—urinary bladder cancer	0.000182	0.00301	CcSEcCtD
Nateglinide—Dizziness—Fluorouracil—urinary bladder cancer	0.000182	0.00301	CcSEcCtD
Nateglinide—Diarrhoea—Cisplatin—urinary bladder cancer	0.000178	0.00295	CcSEcCtD
Nateglinide—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000178	0.00295	CcSEcCtD
Nateglinide—Vomiting—Gemcitabine—urinary bladder cancer	0.000178	0.00295	CcSEcCtD
Nateglinide—Rash—Gemcitabine—urinary bladder cancer	0.000176	0.00292	CcSEcCtD
Nateglinide—Dermatitis—Gemcitabine—urinary bladder cancer	0.000176	0.00292	CcSEcCtD
Nateglinide—Hypersensitivity—Etoposide—urinary bladder cancer	0.000176	0.00291	CcSEcCtD
Nateglinide—Malnutrition—Methotrexate—urinary bladder cancer	0.000175	0.0029	CcSEcCtD
Nateglinide—Vomiting—Fluorouracil—urinary bladder cancer	0.000175	0.0029	CcSEcCtD
Nateglinide—Rash—Fluorouracil—urinary bladder cancer	0.000173	0.00287	CcSEcCtD
Nateglinide—Dermatitis—Fluorouracil—urinary bladder cancer	0.000173	0.00287	CcSEcCtD
Nateglinide—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000172	0.00284	CcSEcCtD
Nateglinide—Asthenia—Etoposide—urinary bladder cancer	0.000171	0.00284	CcSEcCtD
Nateglinide—Immune system disorder—Epirubicin—urinary bladder cancer	0.00017	0.00282	CcSEcCtD
Nateglinide—Back pain—Methotrexate—urinary bladder cancer	0.000169	0.00281	CcSEcCtD
Nateglinide—Pruritus—Etoposide—urinary bladder cancer	0.000169	0.0028	CcSEcCtD
Nateglinide—Nausea—Gemcitabine—urinary bladder cancer	0.000166	0.00275	CcSEcCtD
Nateglinide—Vomiting—Cisplatin—urinary bladder cancer	0.000166	0.00275	CcSEcCtD
Nateglinide—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000165	0.00273	CcSEcCtD
Nateglinide—Rash—Cisplatin—urinary bladder cancer	0.000164	0.00272	CcSEcCtD
Nateglinide—Dermatitis—Cisplatin—urinary bladder cancer	0.000164	0.00272	CcSEcCtD
Nateglinide—Malnutrition—Epirubicin—urinary bladder cancer	0.000164	0.00272	CcSEcCtD
Nateglinide—Diarrhoea—Etoposide—urinary bladder cancer	0.000163	0.00271	CcSEcCtD
Nateglinide—Nausea—Fluorouracil—urinary bladder cancer	0.000163	0.00271	CcSEcCtD
Nateglinide—Back pain—Epirubicin—urinary bladder cancer	0.000158	0.00263	CcSEcCtD
Nateglinide—Dizziness—Etoposide—urinary bladder cancer	0.000158	0.00262	CcSEcCtD
Nateglinide—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000157	0.00261	CcSEcCtD
Nateglinide—Nausea—Cisplatin—urinary bladder cancer	0.000155	0.00256	CcSEcCtD
Nateglinide—Cough—Methotrexate—urinary bladder cancer	0.000153	0.00253	CcSEcCtD
Nateglinide—Vomiting—Etoposide—urinary bladder cancer	0.000152	0.00252	CcSEcCtD
Nateglinide—Malnutrition—Doxorubicin—urinary bladder cancer	0.000152	0.00251	CcSEcCtD
Nateglinide—Rash—Etoposide—urinary bladder cancer	0.00015	0.00249	CcSEcCtD
Nateglinide—Dermatitis—Etoposide—urinary bladder cancer	0.00015	0.00249	CcSEcCtD
Nateglinide—Back pain—Doxorubicin—urinary bladder cancer	0.000147	0.00243	CcSEcCtD
Nateglinide—Palpitations—Epirubicin—urinary bladder cancer	0.000145	0.0024	CcSEcCtD
Nateglinide—Cough—Epirubicin—urinary bladder cancer	0.000143	0.00237	CcSEcCtD
Nateglinide—Nausea—Etoposide—urinary bladder cancer	0.000142	0.00235	CcSEcCtD
Nateglinide—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000138	0.00229	CcSEcCtD
Nateglinide—Palpitations—Doxorubicin—urinary bladder cancer	0.000134	0.00222	CcSEcCtD
Nateglinide—Cough—Doxorubicin—urinary bladder cancer	0.000132	0.00219	CcSEcCtD
Nateglinide—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000129	0.00214	CcSEcCtD
Nateglinide—Dyspepsia—Methotrexate—urinary bladder cancer	0.000126	0.00209	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000123	0.00205	CcSEcCtD
Nateglinide—Fatigue—Methotrexate—urinary bladder cancer	0.000123	0.00204	CcSEcCtD
Nateglinide—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.00012	0.00198	CcSEcCtD
Nateglinide—Dyspepsia—Epirubicin—urinary bladder cancer	0.000118	0.00195	CcSEcCtD
Nateglinide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000117	0.00194	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000115	0.00191	CcSEcCtD
Nateglinide—Fatigue—Epirubicin—urinary bladder cancer	0.000115	0.00191	CcSEcCtD
Nateglinide—Urticaria—Methotrexate—urinary bladder cancer	0.000114	0.00188	CcSEcCtD
Nateglinide—Abdominal pain—Methotrexate—urinary bladder cancer	0.000113	0.00187	CcSEcCtD
Nateglinide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000109	0.00181	CcSEcCtD
Nateglinide—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000109	0.00181	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000107	0.00177	CcSEcCtD
Nateglinide—Fatigue—Doxorubicin—urinary bladder cancer	0.000107	0.00177	CcSEcCtD
Nateglinide—Urticaria—Epirubicin—urinary bladder cancer	0.000106	0.00176	CcSEcCtD
Nateglinide—Abdominal pain—Epirubicin—urinary bladder cancer	0.000106	0.00175	CcSEcCtD
Nateglinide—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000105	0.00175	CcSEcCtD
Nateglinide—Asthenia—Methotrexate—urinary bladder cancer	0.000103	0.0017	CcSEcCtD
Nateglinide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000101	0.00168	CcSEcCtD
Nateglinide—Pruritus—Methotrexate—urinary bladder cancer	0.000101	0.00168	CcSEcCtD
Nateglinide—Hypersensitivity—Epirubicin—urinary bladder cancer	9.85e-05	0.00163	CcSEcCtD
Nateglinide—Urticaria—Doxorubicin—urinary bladder cancer	9.83e-05	0.00163	CcSEcCtD
Nateglinide—Abdominal pain—Doxorubicin—urinary bladder cancer	9.78e-05	0.00162	CcSEcCtD
Nateglinide—Diarrhoea—Methotrexate—urinary bladder cancer	9.78e-05	0.00162	CcSEcCtD
Nateglinide—Asthenia—Epirubicin—urinary bladder cancer	9.59e-05	0.00159	CcSEcCtD
Nateglinide—Pruritus—Epirubicin—urinary bladder cancer	9.46e-05	0.00157	CcSEcCtD
Nateglinide—Dizziness—Methotrexate—urinary bladder cancer	9.45e-05	0.00157	CcSEcCtD
Nateglinide—Diarrhoea—Epirubicin—urinary bladder cancer	9.15e-05	0.00152	CcSEcCtD
Nateglinide—Hypersensitivity—Doxorubicin—urinary bladder cancer	9.11e-05	0.00151	CcSEcCtD
Nateglinide—Vomiting—Methotrexate—urinary bladder cancer	9.08e-05	0.00151	CcSEcCtD
Nateglinide—Rash—Methotrexate—urinary bladder cancer	9.01e-05	0.00149	CcSEcCtD
Nateglinide—Dermatitis—Methotrexate—urinary bladder cancer	9e-05	0.00149	CcSEcCtD
Nateglinide—Asthenia—Doxorubicin—urinary bladder cancer	8.88e-05	0.00147	CcSEcCtD
Nateglinide—Dizziness—Epirubicin—urinary bladder cancer	8.84e-05	0.00147	CcSEcCtD
Nateglinide—Pruritus—Doxorubicin—urinary bladder cancer	8.75e-05	0.00145	CcSEcCtD
Nateglinide—Vomiting—Epirubicin—urinary bladder cancer	8.5e-05	0.00141	CcSEcCtD
Nateglinide—Nausea—Methotrexate—urinary bladder cancer	8.49e-05	0.00141	CcSEcCtD
Nateglinide—Diarrhoea—Doxorubicin—urinary bladder cancer	8.46e-05	0.0014	CcSEcCtD
Nateglinide—Rash—Epirubicin—urinary bladder cancer	8.43e-05	0.0014	CcSEcCtD
Nateglinide—Dermatitis—Epirubicin—urinary bladder cancer	8.42e-05	0.0014	CcSEcCtD
Nateglinide—Dizziness—Doxorubicin—urinary bladder cancer	8.18e-05	0.00136	CcSEcCtD
Nateglinide—Nausea—Epirubicin—urinary bladder cancer	7.94e-05	0.00132	CcSEcCtD
Nateglinide—Vomiting—Doxorubicin—urinary bladder cancer	7.87e-05	0.0013	CcSEcCtD
Nateglinide—Rash—Doxorubicin—urinary bladder cancer	7.8e-05	0.00129	CcSEcCtD
Nateglinide—Dermatitis—Doxorubicin—urinary bladder cancer	7.79e-05	0.00129	CcSEcCtD
Nateglinide—Nausea—Doxorubicin—urinary bladder cancer	7.35e-05	0.00122	CcSEcCtD
Nateglinide—ABCC4—Hemostasis—IL2—urinary bladder cancer	2.1e-05	0.000252	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—GPX1—urinary bladder cancer	2.09e-05	0.000251	CbGpPWpGaD
Nateglinide—SLC22A6—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.09e-05	0.00025	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—ERCC2—urinary bladder cancer	2.09e-05	0.00025	CbGpPWpGaD
Nateglinide—PPARG—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.08e-05	0.000249	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—RRM2—urinary bladder cancer	2.07e-05	0.000248	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PRSS3—urinary bladder cancer	2.07e-05	0.000248	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	2.06e-05	0.000247	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—ERCC2—urinary bladder cancer	2.06e-05	0.000247	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	2.04e-05	0.000245	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—MMP9—urinary bladder cancer	2.04e-05	0.000245	CbGpPWpGaD
Nateglinide—SLC16A1—Hemostasis—KRAS—urinary bladder cancer	2.04e-05	0.000244	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—MTHFR—urinary bladder cancer	2.02e-05	0.000243	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—RRM2—urinary bladder cancer	2.01e-05	0.000241	CbGpPWpGaD
Nateglinide—PPARG—Gene Expression—ERCC2—urinary bladder cancer	1.98e-05	0.000238	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—MTHFR—urinary bladder cancer	1.96e-05	0.000235	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—EP300—urinary bladder cancer	1.93e-05	0.000232	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—MTHFR—urinary bladder cancer	1.93e-05	0.000232	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—HPGDS—urinary bladder cancer	1.92e-05	0.00023	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—ENO2—urinary bladder cancer	1.92e-05	0.00023	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—TYMP—urinary bladder cancer	1.92e-05	0.00023	CbGpPWpGaD
Nateglinide—ABCC4—Hemostasis—EP300—urinary bladder cancer	1.89e-05	0.000226	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—SRC—urinary bladder cancer	1.88e-05	0.000225	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—GSTT1—urinary bladder cancer	1.86e-05	0.000223	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—ENO2—urinary bladder cancer	1.86e-05	0.000223	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—HPGDS—urinary bladder cancer	1.86e-05	0.000223	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	1.85e-05	0.000222	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.85e-05	0.000222	CbGpPWpGaD
Nateglinide—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	1.84e-05	0.000221	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—NQO1—urinary bladder cancer	1.84e-05	0.000221	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	1.84e-05	0.00022	CbGpPWpGaD
Nateglinide—ABCC4—Hemostasis—SRC—urinary bladder cancer	1.83e-05	0.00022	CbGpPWpGaD
Nateglinide—PPARG—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.81e-05	0.000217	CbGpPWpGaD
Nateglinide—SLC16A1—Hemostasis—TP53—urinary bladder cancer	1.81e-05	0.000217	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—GSTT1—urinary bladder cancer	1.8e-05	0.000216	CbGpPWpGaD
Nateglinide—PPARG—Generic Transcription Pathway—MYC—urinary bladder cancer	1.79e-05	0.000215	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—GSTP1—urinary bladder cancer	1.78e-05	0.000214	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.78e-05	0.000214	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.78e-05	0.000213	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	1.75e-05	0.00021	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	1.74e-05	0.000208	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—NAT2—urinary bladder cancer	1.73e-05	0.000208	CbGpPWpGaD
Nateglinide—SLC16A1—Hemostasis—HRAS—urinary bladder cancer	1.73e-05	0.000208	CbGpPWpGaD
Nateglinide—PPARG—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.73e-05	0.000207	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	1.71e-05	0.000205	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	1.69e-05	0.000203	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—TYMS—urinary bladder cancer	1.66e-05	0.000199	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.66e-05	0.000199	CbGpPWpGaD
Nateglinide—PPARG—Gene Expression—ESR1—urinary bladder cancer	1.66e-05	0.000199	CbGpPWpGaD
Nateglinide—ALB—Metabolism—TYMP—urinary bladder cancer	1.65e-05	0.000198	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—EGFR—urinary bladder cancer	1.65e-05	0.000198	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—GSTM1—urinary bladder cancer	1.64e-05	0.000197	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—PPARG—urinary bladder cancer	1.64e-05	0.000197	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—NCOR1—urinary bladder cancer	1.64e-05	0.000197	CbGpPWpGaD
Nateglinide—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	1.61e-05	0.000193	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—PPARG—urinary bladder cancer	1.59e-05	0.000191	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.59e-05	0.00019	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—CREBBP—urinary bladder cancer	1.58e-05	0.000189	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—GPX1—urinary bladder cancer	1.57e-05	0.000188	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—TNF—urinary bladder cancer	1.57e-05	0.000188	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—PPARG—urinary bladder cancer	1.57e-05	0.000188	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—KRAS—urinary bladder cancer	1.56e-05	0.000187	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.56e-05	0.000187	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.55e-05	0.000186	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—NQO1—urinary bladder cancer	1.55e-05	0.000185	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—ERCC2—urinary bladder cancer	1.54e-05	0.000185	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—GSTP1—urinary bladder cancer	1.53e-05	0.000184	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—CREBBP—urinary bladder cancer	1.53e-05	0.000183	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—PLAU—urinary bladder cancer	1.52e-05	0.000182	CbGpPWpGaD
Nateglinide—ABCC4—Hemostasis—KRAS—urinary bladder cancer	1.52e-05	0.000182	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—CREBBP—urinary bladder cancer	1.51e-05	0.000181	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—NQO1—urinary bladder cancer	1.5e-05	0.00018	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—RRM2—urinary bladder cancer	1.5e-05	0.00018	CbGpPWpGaD
Nateglinide—ALB—Metabolism—NAT2—urinary bladder cancer	1.49e-05	0.000179	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.48e-05	0.000178	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.47e-05	0.000177	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.47e-05	0.000177	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.45e-05	0.000174	CbGpPWpGaD
Nateglinide—PPARG—Gene Expression—CREBBP—urinary bladder cancer	1.45e-05	0.000174	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—MTHFR—urinary bladder cancer	1.45e-05	0.000174	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—TYMS—urinary bladder cancer	1.43e-05	0.000171	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—NCOR1—urinary bladder cancer	1.41e-05	0.000169	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—GSTM1—urinary bladder cancer	1.41e-05	0.000169	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	1.39e-05	0.000166	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—ENO2—urinary bladder cancer	1.39e-05	0.000166	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—TYMP—urinary bladder cancer	1.36e-05	0.000164	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.36e-05	0.000163	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—TYMP—urinary bladder cancer	1.35e-05	0.000162	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—GPX1—urinary bladder cancer	1.35e-05	0.000162	CbGpPWpGaD
Nateglinide—ABCC4—Hemostasis—TP53—urinary bladder cancer	1.35e-05	0.000162	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.35e-05	0.000161	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	1.34e-05	0.000161	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—ERCC2—urinary bladder cancer	1.32e-05	0.000159	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—HRAS—urinary bladder cancer	1.32e-05	0.000159	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.3e-05	0.000156	CbGpPWpGaD
Nateglinide—ABCC4—Hemostasis—HRAS—urinary bladder cancer	1.29e-05	0.000155	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—PTGS2—urinary bladder cancer	1.29e-05	0.000155	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	1.29e-05	0.000155	CbGpPWpGaD
Nateglinide—ALB—Metabolism—RRM2—urinary bladder cancer	1.29e-05	0.000155	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.27e-05	0.000152	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—CREBBP—urinary bladder cancer	1.25e-05	0.00015	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—PTGS2—urinary bladder cancer	1.25e-05	0.00015	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—GSTP1—urinary bladder cancer	1.25e-05	0.00015	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—MTHFR—urinary bladder cancer	1.25e-05	0.000149	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—IGF1—urinary bladder cancer	1.24e-05	0.000148	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—NAT2—urinary bladder cancer	1.23e-05	0.000148	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—PTGS2—urinary bladder cancer	1.23e-05	0.000148	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—NAT2—urinary bladder cancer	1.22e-05	0.000147	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.21e-05	0.000145	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.21e-05	0.000145	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—TYMS—urinary bladder cancer	1.2e-05	0.000144	CbGpPWpGaD
Nateglinide—ALB—Metabolism—ENO2—urinary bladder cancer	1.19e-05	0.000143	CbGpPWpGaD
Nateglinide—ALB—Metabolism—HPGDS—urinary bladder cancer	1.19e-05	0.000143	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.19e-05	0.000142	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	1.19e-05	0.000142	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	1.19e-05	0.000142	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—TYMS—urinary bladder cancer	1.16e-05	0.000139	CbGpPWpGaD
Nateglinide—ALB—Metabolism—GSTT1—urinary bladder cancer	1.16e-05	0.000139	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—NCOR1—urinary bladder cancer	1.15e-05	0.000138	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—GSTM1—urinary bladder cancer	1.15e-05	0.000138	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.14e-05	0.000137	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.14e-05	0.000137	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—GPX1—urinary bladder cancer	1.13e-05	0.000136	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—RHOA—urinary bladder cancer	1.13e-05	0.000136	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—CREBBP—urinary bladder cancer	1.13e-05	0.000135	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—PTEN—urinary bladder cancer	1.12e-05	0.000135	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—NQO1—urinary bladder cancer	1.12e-05	0.000134	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.12e-05	0.000134	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	1.11e-05	0.000134	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—GPX1—urinary bladder cancer	1.1e-05	0.000132	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—PTEN—urinary bladder cancer	1.09e-05	0.000131	CbGpPWpGaD
Nateglinide—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.08e-05	0.00013	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—ERCC2—urinary bladder cancer	1.08e-05	0.00013	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—PTEN—urinary bladder cancer	1.08e-05	0.000129	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—EP300—urinary bladder cancer	1.07e-05	0.000129	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—RRM2—urinary bladder cancer	1.06e-05	0.000128	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.06e-05	0.000127	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	1.05e-05	0.000126	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—EP300—urinary bladder cancer	1.04e-05	0.000125	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—EP300—urinary bladder cancer	1.03e-05	0.000123	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—MTHFR—urinary bladder cancer	1.02e-05	0.000122	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PPARG—urinary bladder cancer	1.01e-05	0.000121	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ENO2—urinary bladder cancer	9.86e-06	0.000118	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	9.86e-06	0.000118	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	9.77e-06	0.000117	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ENO2—urinary bladder cancer	9.77e-06	0.000117	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	9.72e-06	0.000117	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—CREBBP—urinary bladder cancer	9.7e-06	0.000116	CbGpPWpGaD
Nateglinide—ALB—Metabolism—NQO1—urinary bladder cancer	9.63e-06	0.000115	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	9.56e-06	0.000115	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—IL2—urinary bladder cancer	9.51e-06	0.000114	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	9.48e-06	0.000114	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.34e-06	0.000112	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	9.33e-06	0.000112	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	9.32e-06	0.000112	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PTGS2—urinary bladder cancer	9.24e-06	0.000111	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—TYMP—urinary bladder cancer	8.92e-06	0.000107	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—TYMS—urinary bladder cancer	8.67e-06	0.000104	CbGpPWpGaD
Nateglinide—PPARG—Gene Expression—MYC—urinary bladder cancer	8.62e-06	0.000103	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	8.57e-06	0.000103	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	8.57e-06	0.000103	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—EP300—urinary bladder cancer	8.53e-06	0.000102	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PPARG—urinary bladder cancer	8.49e-06	0.000102	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—SRC—urinary bladder cancer	8.3e-06	9.95e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PPARG—urinary bladder cancer	8.23e-06	9.87e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—GPX1—urinary bladder cancer	8.2e-06	9.84e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	8.16e-06	9.79e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.14e-06	9.77e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—NAT2—urinary bladder cancer	8.06e-06	9.67e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PTEN—urinary bladder cancer	8.06e-06	9.67e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	8.05e-06	9.66e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—GSTP1—urinary bladder cancer	8.03e-06	9.63e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—NQO1—urinary bladder cancer	7.95e-06	9.53e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PTGS2—urinary bladder cancer	7.94e-06	9.53e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—CREBBP—urinary bladder cancer	7.91e-06	9.49e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—NQO1—urinary bladder cancer	7.88e-06	9.45e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.77e-06	9.32e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—EP300—urinary bladder cancer	7.69e-06	9.22e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.64e-06	9.17e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	7.57e-06	9.08e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—TYMS—urinary bladder cancer	7.46e-06	8.95e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—NCOR1—urinary bladder cancer	7.38e-06	8.85e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—GSTM1—urinary bladder cancer	7.38e-06	8.85e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—GPX1—urinary bladder cancer	7.06e-06	8.47e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—RRM2—urinary bladder cancer	6.96e-06	8.35e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—ERCC2—urinary bladder cancer	6.94e-06	8.32e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PTEN—urinary bladder cancer	6.93e-06	8.31e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—KRAS—urinary bladder cancer	6.87e-06	8.24e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	6.68e-06	8.01e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.67e-06	8e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	6.63e-06	7.95e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—EP300—urinary bladder cancer	6.61e-06	7.93e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	6.57e-06	7.88e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—MTHFR—urinary bladder cancer	6.52e-06	7.82e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PTGS2—urinary bladder cancer	6.48e-06	7.77e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ENO2—urinary bladder cancer	6.45e-06	7.73e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	6.45e-06	7.73e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.36e-06	7.63e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	6.25e-06	7.5e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—TYMS—urinary bladder cancer	6.16e-06	7.39e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PPARG—urinary bladder cancer	6.14e-06	7.36e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—TYMS—urinary bladder cancer	6.11e-06	7.33e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—TP53—urinary bladder cancer	6.11e-06	7.32e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	6.09e-06	7.31e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	6.09e-06	7.31e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	6.04e-06	7.24e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	6.04e-06	7.24e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	5.9e-06	7.07e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—HRAS—urinary bladder cancer	5.84e-06	7e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GPX1—urinary bladder cancer	5.83e-06	7e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PTEN—urinary bladder cancer	5.83e-06	6.99e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GPX1—urinary bladder cancer	5.78e-06	6.94e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	5.73e-06	6.87e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	5.68e-06	6.81e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PTEN—urinary bladder cancer	5.65e-06	6.77e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—EP300—urinary bladder cancer	5.56e-06	6.67e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—EP300—urinary bladder cancer	5.39e-06	6.46e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	5.38e-06	6.46e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	5.34e-06	6.4e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PPARG—urinary bladder cancer	5.29e-06	6.34e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—NQO1—urinary bladder cancer	5.2e-06	6.23e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CREBBP—urinary bladder cancer	5.08e-06	6.09e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	4.83e-06	5.79e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PPARG—urinary bladder cancer	4.37e-06	5.24e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	4.33e-06	5.2e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PPARG—urinary bladder cancer	4.33e-06	5.19e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PTEN—urinary bladder cancer	4.21e-06	5.05e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	4.19e-06	5.03e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PTGS2—urinary bladder cancer	4.16e-06	4.99e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	4.16e-06	4.99e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—TYMS—urinary bladder cancer	4.03e-06	4.83e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—EP300—urinary bladder cancer	4.02e-06	4.82e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	3.98e-06	4.78e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	3.98e-06	4.78e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GPX1—urinary bladder cancer	3.81e-06	4.57e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	3.74e-06	4.49e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PTEN—urinary bladder cancer	3.63e-06	4.35e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	3.52e-06	4.22e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—EP300—urinary bladder cancer	3.46e-06	4.15e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	3.43e-06	4.12e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	3.4e-06	4.08e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PTEN—urinary bladder cancer	2.99e-06	3.59e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PTEN—urinary bladder cancer	2.97e-06	3.56e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—EP300—urinary bladder cancer	2.86e-06	3.43e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.85e-06	3.42e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—EP300—urinary bladder cancer	2.83e-06	3.4e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.74e-06	3.29e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.25e-06	2.69e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.96e-06	2.35e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.87e-06	2.24e-05	CbGpPWpGaD
